{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,15]],"date-time":"2024-09-15T15:45:45Z","timestamp":1726415145892},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,7,23]],"date-time":"2022-07-23T00:00:00Z","timestamp":1658534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,7,23]],"date-time":"2022-07-23T00:00:00Z","timestamp":1658534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s40256-022-00544-7","type":"journal-article","created":{"date-parts":[[2022,7,23]],"date-time":"2022-07-23T01:02:17Z","timestamp":1658538137000},"page":"595-600","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Do Oral Factor Xa Inhibitors have a Role in Patients with Mechanical Heart Valves?"],"prefix":"10.1007","volume":"22","author":[{"given":"Shisi","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,7,23]]},"reference":[{"issue":"5","key":"544_CR1","first-page":"e72","volume":"143","author":"CM Otto","year":"2021","unstructured":"Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP 3rd, Gentile F, et al. 2020 ACC\/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021;143(5):e72\u2013227.","journal-title":"Circulation"},{"issue":"5","key":"544_CR2","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/nrcardio.2017.223","volume":"15","author":"JH Levy","year":"2018","unstructured":"Levy JH, Douketis J, Weitz JI. Reversal agents for non-vitamin K antagonist oral anticoagulants. Nat Rev Cardiol. 2018;15(5):273\u201381.","journal-title":"Nat Rev Cardiol"},{"issue":"10264","key":"544_CR3","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1016\/S0140-6736(20)32439-9","volume":"396","author":"N Chan","year":"2020","unstructured":"Chan N, Sobieraj-Teague M, Eikelboom JW. Direct oral anticoagulants: evidence and unresolved issues. Lancet. 2020;396(10264):1767\u201376.","journal-title":"Lancet"},{"issue":"4","key":"544_CR4","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1111\/bjh.16528","volume":"190","author":"D Pastori","year":"2020","unstructured":"Pastori D, Lip GYH, Poli D, Antonucci E, Rubino L, Menichelli D, et al. Determinants of low-quality warfarin anticoagulation in patients with mechanical prosthetic heart valves. The nationwide PLECTRUM study. Br J Haematol. 2020;190(4):588\u201393.","journal-title":"Br J Haematol."},{"issue":"45","key":"544_CR5","doi-asserted-by":"publisher","first-page":"3370","DOI":"10.1093\/eurheartj\/ehx199","volume":"38","author":"NM Korteland","year":"2017","unstructured":"Korteland NM, Etnel JRG, Arabkhani B, Mokhles MM, Mohamad A, Roos-Hesselink JW, et al. Mechanical aortic valve replacement in non-elderly adults: meta-analysis and microsimulation. Eur Heart J. 2017;38(45):3370\u20137.","journal-title":"Eur Heart J"},{"issue":"5","key":"544_CR6","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.3390\/molecules26051425","volume":"26","author":"D Menichelli","year":"2021","unstructured":"Menichelli D, Poli D, Antonucci E, Cammisotto V, Testa S, Pignatelli P, et al. Comparison of anticoagulation quality between acenocoumarol and warfarin in patients with mechanical prosthetic heart valves: insights from the Nationwide PLECTRUM study. Molecules. 2021;26(5):1425.","journal-title":"Molecules"},{"issue":"13","key":"544_CR7","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1161\/CIRCULATIONAHA.118.035612","volume":"138","author":"A Aimo","year":"2018","unstructured":"Aimo A, Giugliano RP, De Caterina R. Non-Vitamin K antagonist oral anticoagulants for mechanical heart valves: is the door still open? Circulation. 2018;138(13):1356\u201365.","journal-title":"Circulation"},{"issue":"6","key":"544_CR8","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.ahj.2012.03.011","volume":"163","author":"F Van de Werf","year":"2012","unstructured":"Van de Werf F, Brueckmann M, Connolly SJ, Friedman J, Granger CB, Hartter S, et al. A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: THE randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN). Am Heart J. 2012;163(6):931-7 e1.","journal-title":"Am Heart J"},{"issue":"13","key":"544_CR9","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1056\/NEJMoa1300615","volume":"369","author":"JW Eikelboom","year":"2013","unstructured":"Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack MJ, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013;369(13):1206\u201314.","journal-title":"N Engl J Med"},{"issue":"8","key":"544_CR10","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.115.002322","volume":"4","author":"IH Jaffer","year":"2015","unstructured":"Jaffer IH, Stafford AR, Fredenburgh JC, Whitlock RP, Chan NC, Weitz JI. Dabigatran is less effective than warfarin at attenuating mechanical heart valve-induced thrombin generation. J Am Heart Assoc. 2015;4(8): e002322.","journal-title":"J Am Heart Assoc"},{"issue":"10","key":"544_CR11","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1111\/j.1538-7836.2007.02710.x","volume":"5","author":"KG Mann","year":"2007","unstructured":"Mann KG, Whelihan MF, Butenas S, Orfeo T. Citrate anticoagulation and the dynamics of thrombin generation. J Thromb Haemost. 2007;5(10):2055\u201361.","journal-title":"J Thromb Haemost"},{"issue":"2","key":"544_CR12","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1161\/CIRCULATIONAHA.115.015242","volume":"132","author":"IM van Hagen","year":"2015","unstructured":"van Hagen IM, Roos-Hesselink JW, Ruys TP, Merz WM, Goland S, Gabriel H, et al. Pregnancy in women with a mechanical heart valve: data of the European Society of Cardiology Registry of Pregnancy and Cardiac Disease (ROPAC). Circulation. 2015;132(2):132\u201342.","journal-title":"Circulation"},{"issue":"4","key":"544_CR13","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s11239-011-0621-6","volume":"32","author":"A Kaeberich","year":"2011","unstructured":"Kaeberich A, Reindl I, Raaz U, Maegdefessel L, Vogt A, Linde T, et al. Comparison of unfractionated heparin, low-molecular-weight heparin, low-dose and high-dose rivaroxaban in preventing thrombus formation on mechanical heart valves: results of an in vitro study. J Thromb Thrombolysis. 2011;32(4):417\u201325.","journal-title":"J Thromb Thrombolysis"},{"issue":"2","key":"544_CR14","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.athoracsur.2019.10.091","volume":"110","author":"IH Jaffer","year":"2020","unstructured":"Jaffer IH, Fredenburgh JC, Stafford A, Whitlock RP, Weitz JI. Rivaroxaban and dabigatran for suppression of mechanical heart valve-induced thrombin generation. Ann Thorac Surg. 2020;110(2):582\u201390.","journal-title":"Ann Thorac Surg"},{"issue":"5","key":"544_CR15","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1093\/ejcts\/ezt545","volume":"45","author":"LE Greiten","year":"2014","unstructured":"Greiten LE, McKellar SH, Rysavy J, Schaff HV. Effectiveness of rivaroxaban for thromboprophylaxis of prosthetic heart valves in a porcine heterotopic valve model. Eur J Cardiothorac Surg. 2014;45(5):914\u20139.","journal-title":"Eur J Cardiothorac Surg"},{"issue":"5","key":"544_CR16","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1161\/ATVBAHA.116.308649","volume":"37","author":"PA Lester","year":"2017","unstructured":"Lester PA, Coleman DM, Diaz JA, Jackson TO, Hawley AE, Mathues AR, et al. Apixaban versus warfarin for mechanical heart valve thromboprophylaxis in a swine aortic heterotopic valve model. Arterioscler Thromb Vasc Biol. 2017;37(5):942\u20138.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"11","key":"544_CR17","doi-asserted-by":"publisher","first-page":"652","DOI":"10.12968\/hmed.2018.79.11.652","volume":"79","author":"P Shukla","year":"2018","unstructured":"Shukla P, Ashraf I, Aghoram P. Apixaban for stroke prevention in a patient with a mechanical heart valve. Br J Hosp Med (Lond). 2018;79(11):652\u20133.","journal-title":"Br J Hosp Med (Lond)"},{"issue":"7","key":"544_CR18","doi-asserted-by":"publisher","first-page":"ytab285","DOI":"10.1093\/ehjcr\/ytab285","volume":"5","author":"JY Eom","year":"2021","unstructured":"Eom JY, Shin JK, Kwon CH. Apixaban use in an atrial fibrillation patient with double mechanical heart valves: a case report. Eur Heart J Case Rep. 2021;5(7):ytab285.","journal-title":"Eur Heart J Case Rep."},{"issue":"3\u20134","key":"544_CR19","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1159\/000501361","volume":"143","author":"DM Carvalho Silva","year":"2019","unstructured":"Carvalho Silva DM, Braga A, de Jesus I, Neves J. Mechanical prosthetic heart valve thrombosis in a patient receiving rivaroxaban. Cardiology. 2019;143(3\u20134):116\u201320.","journal-title":"Cardiology"},{"issue":"2","key":"544_CR20","first-page":"73","volume":"13","author":"V Kumar","year":"2017","unstructured":"Kumar V, Kelly S, Raizada A, Yee J, Anuwatworn A, Stys A, et al. Mechanical valve thrombosis on rivaroxaban: are novel anticoagulants really an option? Methodist Debakey. Cardiovasc J. 2017;13(2):73\u20135.","journal-title":"Cardiovasc J"},{"issue":"6","key":"544_CR21","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1002\/pds.4778","volume":"28","author":"N Vinter","year":"2019","unstructured":"Vinter N, Linder M, Andersen M, Pedersen AB, Madsen M, Schachterle SE, et al. Classification and characteristics of on-label and off-label apixaban use in Denmark and Sweden. Pharmacoepidemiol Drug Saf. 2019;28(6):867\u201378.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"544_CR22","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1080\/03007995.2021.1885365","volume":"37","author":"HJ Li","year":"2021","unstructured":"Li HJ, Lin SY, Lin FJ, Hung CS, Wang CC. Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation and valvular heart disease. Curr Med Res Opin. 2021;37(4):535\u201342.","journal-title":"Curr Med Res Opin"},{"issue":"6","key":"544_CR23","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.amjcard.2018.06.015","volume":"122","author":"AR Duraes","year":"2018","unstructured":"Duraes AR, Bitar YSL, Lima MLG, Santos CC, Schonhofen IS, Filho JAL, et al. Usefulness and safety of rivaroxaban in patients following isolated mitral valve replacement with a mechanical prosthesis. Am J Cardiol. 2018;122(6):1047\u201350.","journal-title":"Am J Cardiol"},{"key":"544_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.thromres.2019.12.005","volume":"186","author":"E Roost","year":"2020","unstructured":"Roost E, Weber A, Alberio L, Englberger L, Reineke D, Keller D, et al. Rivaroxaban in patients with mechanical heart valves: a pilot study. Thromb Res. 2020;186:1\u20136.","journal-title":"Thromb Res"},{"issue":"4","key":"544_CR25","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s40268-018-0249-5","volume":"18","author":"AR Duraes","year":"2018","unstructured":"Duraes AR, de Souza Lima Bitar Y, Filho JAL, Schonhofen IS, Camara EJN, Roever L, et al. Rivaroxaban versus warfarin in patients with mechanical heart valve: rationale and design of the RIWA study. Drugs R D. 2018;18(4):303\u20138.","journal-title":"Drugs R D."},{"issue":"3","key":"544_CR26","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s40256-020-00449-3","volume":"21","author":"AR Duraes","year":"2021","unstructured":"Duraes AR, de Souza Lima Bitar Y, Schonhofen IS, Travassos KSO, Pereira LV, Filho JAL, et al. Rivaroxaban versus warfarin in patients with mechanical heart valves: open-label, proof-of-concept trial\u2014the RIWA study. Am J Cardiovasc Drugs. 2021;21(3):363\u201371.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"6","key":"544_CR27","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1001\/jamasurg.2018.0374","volume":"153","author":"A Verma","year":"2018","unstructured":"Verma A, Ha ACT, Rutka JT, Verma S. What surgeons should know about non-vitamin K oral anticoagulants: a review. JAMA Surg. 2018;153(6):577\u201385.","journal-title":"JAMA Surg"},{"issue":"24","key":"544_CR28","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1016\/j.jacc.2016.09.958","volume":"68","author":"GD Dangas","year":"2016","unstructured":"Dangas GD, Weitz JI, Giustino G, Makkar R, Mehran R. Prosthetic heart valve thrombosis. J Am Coll Cardiol. 2016;68(24):2670\u201389.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"544_CR29","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1016\/j.thromres.2014.09.030","volume":"134","author":"S Zhu","year":"2014","unstructured":"Zhu S, Diamond SL. Contact activation of blood coagulation on a defined kaolin\/collagen surface in a microfluidic assay. Thromb Res. 2014;134(6):1335\u201343.","journal-title":"Thromb Res"},{"issue":"10","key":"544_CR30","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.imbio.2016.06.005","volume":"221","author":"R Wiegner","year":"2016","unstructured":"Wiegner R, Chakraborty S, Huber-Lang M. Complement-coagulation crosstalk on cellular and artificial surfaces. Immunobiology. 2016;221(10):1073\u20139.","journal-title":"Immunobiology"},{"issue":"1","key":"544_CR31","doi-asserted-by":"publisher","first-page":"78","DOI":"10.4244\/EIJV5I1A12","volume":"5","author":"S Noble","year":"2009","unstructured":"Noble S, Asgar A, Cartier R, Virmani R, Bonan R. Anatomo-pathological analysis after CoreValve Revalving system implantation. EuroIntervention. 2009;5(1):78\u201385.","journal-title":"EuroIntervention"},{"issue":"21","key":"544_CR32","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1056\/NEJMoa1509233","volume":"373","author":"RR Makkar","year":"2015","unstructured":"Makkar RR, Fontana G, Jilaihawi H, Chakravarty T, Kofoed KF, De Backer O, et al. Possible subclinical leaflet thrombosis in bioprosthetic aortic valves. N Engl J Med. 2015;373(21):2015\u201324.","journal-title":"N Engl J Med"},{"key":"544_CR33","doi-asserted-by":"crossref","unstructured":"Chu MWA, Ruel M, Graeve A, Gerdisch MW, Damiano RJ Jr, Smith RL 2nd, et al. Low-dose versus standard warfarin after mechanical mitral valve replacement: a randomized controlled trial. Ann Thorac Surg. 2022.","DOI":"10.1016\/j.athoracsur.2022.01.015"},{"key":"544_CR34","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ahj.2020.06.014","volume":"227","author":"OK Jawitz","year":"2020","unstructured":"Jawitz OK, Wang TY, Lopes RD, Chavez A, Boyer B, Kim H, et al. Rationale and design of PROACT Xa: a randomized, multicenter, open-label, clinical trial to evaluate the efficacy and safety of apixaban versus warfarin in patients with a mechanical On-X Aortic Heart Valve. Am Heart J. 2020;227:91\u20139.","journal-title":"Am Heart J"},{"key":"544_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.768730","volume":"8","author":"D Lin","year":"2021","unstructured":"Lin D, Chen Y, Yong J, Wu S, Zhou Y, Li W, et al. Does warfarin or rivaroxaban at low anticoagulation intensity provide a survival benefit to Asian patients with atrial fibrillation? Front Cardiovasc Med. 2021;8: 768730.","journal-title":"Front Cardiovasc Med."},{"issue":"3","key":"544_CR36","first-page":"164","volume":"38","author":"The Group of Valve Surgery, Chinese Society for Thoracic and Cardiovascular Surgery","year":"2022","unstructured":"The Group of Valve Surgery, Chinese Society for Thoracic and Cardiovascular Surgery. Consensus of Chinese experts on anticoagulant therapy in cardiac valve surgery. Chin J Thorac Cardiovasc Surg. 2022;38(3):164\u201374.","journal-title":"Chin J Thorac Cardiovasc Surg."},{"issue":"2","key":"544_CR37","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.46026","volume":"5","author":"JT Huang","year":"2022","unstructured":"Huang JT, Chan YH, Wu VC, Cheng YT, Chen DY, Lin CP, et al. Analysis of anticoagulation therapy and anticoagulation-related outcomes among Asian patients after mechanical valve replacement. JAMA Netw Open. 2022;5(2): e2146026.","journal-title":"JAMA Netw Open"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-022-00544-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-022-00544-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-022-00544-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T01:05:00Z","timestamp":1667178300000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-022-00544-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,23]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["544"],"URL":"https:\/\/doi.org\/10.1007\/s40256-022-00544-7","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"type":"print","value":"1175-3277"},{"type":"electronic","value":"1179-187X"}],"subject":[],"published":{"date-parts":[[2022,7,23]]},"assertion":[{"value":"30 June 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was supported by Education Reform Project of Army Medical University (No. 2021B24).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Shisi Li and Yong Zhang declare that they have no potential conflicts of interest that might be relevant to the contents of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"SSL conceptualization, data curation, and writing; YZ conceptualization, writing, and reviewing.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}